Method for prevention and treatment of lipidemic metabolic disorders combined with insulin-independent diabetes mellitus by drinking balneotherapy using natural mineral halogenated water

FIELD: medicine.

SUBSTANCE: halogenated hydrocarbonate chloride sodium, alkaline, boron, high-magnesium, iodine and fluorine natural mineral water 'Lazarevskaya Tselebnaya' No. 84-E of the Volkonskoye deposit in Sochi is taken according to the following procedure: 18-20 minutes before meals in small sips, 6 times a day daily in a dose of 180-200 ml at t=24-25°C for 40 days every 3-5 days with taking the above natural halogenated mineral water in the same amounts for the following 45 days. The therapeutic course makes 3 years and repeats every 3 months.

EFFECT: method enables reducing metabolic disorders by a systemic insulin-producing effect in a combination with a hypolipidemic and diuretic component.

3 cl, 4 tbl, 2 ex

 

The technical field

The invention relates to medicine, in particular, to the problem of prevention and treatment of patients with metabolic disorders by type of lipidemia (E 78 ICD-X) in combination with non-insulin-dependent diabetes mellitus (E 11 ICD-X).

The level of technology

Prevention and treatment of patients with metabolic disorders by type of lipidemia (E 78 ICD-X) in combination with non-insulin-dependent diabetes mellitus (E 11 ICD-X) is called domestic and foreign researchers (I.E. Chazova, SHE Kathuria, 2001 [Annex 1, item 7]; B.A. Sidorenko, Y.A. Suvorov, 2005 [Annex 1, item 6]; GEOL. Belenkov et al., 2008 [Annex 1, p.2]; M.N. Mamedov, 2010 [Annex 1, item 4]; I.I. Dedov et al., 2012 [Annex 1, section 3]; M. Paul, D. Ganten, 2002 [Annex 1, 14]; D. Evequoz, P. Erne, 2008 [Annex 1, paragraph 10]; M. Iriarte, R. Caso, N. Mugra et al., 2012 [Annex 1, section 12]) one of the most urgent problems of the present. Moreover, R. Secree, J. Shaw, P. Zimmet (2011) [Annex 1, § 15] point to the fact that the dyslipoproteinemia act as a risk factor in the development of atherosclerosis, and simultaneously diabetes, a R.W. Nestro (2011) [Annex 1, item 13] indicates the total syndrome of hypertension in these diseases, which (in his opinion) "due to a single etiopathogenetic mechanism of development of hyperosmolarity plasma that occurs due to a sharp reduction of unclutch the second liquid at deficiency of sodium in these patients". In this regard, actualized the problem of cellular and extracellular dehydration that the Ukrainian health resort E.N. Marcinik, L.N., Pastarus, I. Tishchenko (2008) [Annex 1, item 5] propose to fill various drinking natural modes hydrocarbonate sodium-calcium mineral waters. Determining the relevance of the chosen theme of scientific research, should indicate that the leading national school of cardiology (E.I. Chazov, I. Martynov, BC Gasilin, R.S. Karpov, P. Belousov and others) think "meet the increased demand of oxygen is one of the leading factors in the prevention of spontaneous formation of microaggregates platelets. At the same time, according to European researchers (K. Swedberg, J. Cleland, N. Dargie et al., 2005 [Annex 1, item 16]) such coloradoavalanche detected at 23-25% of patients with non-insulin dependent diabetes mellitus type II. Generalization (in the framework of its thematic review of leading sources) modern scientific ideas about therapeutic potential of medicinal or non-medicinal compensation schemes combined clinical manifestations of non-insulin-dependent diabetes mellitus and metabolic disorders by type of lipidemia has allowed to establish, that in 70% of cases dispensary observation (at the level of municipal health care institutions) individuals with concomitant pathology is th E 11 and E 78 ICD-X does not pass the compulsory stage of sanatorium rehabilitation, including drinking balneotherapy.

Table 1
Modern scientific ideas about therapeutic potential of medicinal and non-medicinal compensation schemes combined clinical manifestations of diabetes mellitus and lipidemia.
The implementation methodology previously known and claimed copyright schemesScientific support mechanism for compensation of the original combined violations:
1. Principles: the use of (low tolerance to physical load and the total duration of painless myocardial ischemia more than 10 min/day.) drugs main antianginal groups, i.e. nitrates, calcium antagonists, b-blockers, which allows to interrupt the chain "ischemic cascade, leading to the emergence of "silent" ischemia in patients with asymptomatic myocardial ischemia (authors of theory - 3.A.Cairns, M. Gent, F.Singer, et al., 2003; J.M. Cruickshank, 2004).
2. Tools regeneration: 2.1) impaired glucose tolerance in patients with non-insulin dependent diabetes mellitus type II; 2.2) insulin resistance and initially impaired function of b-cells; 2.3) normal level synthesis inhibitor of the plasminogen activator is 1 (PAI-1); 2.4) the level of expression of poly - and mononuclear gene vectors glucose (including GLUT-4).
a) high efficiency of nitrates because of their ability to lower the tone of the coronary arteries, coronary resistance and the need of oxygen; b) efficiency and b-adrenergic blockers (such labetalola), reduce the duration of episodes of painless ST-segment depression at 70-75%; C) receiving prolonged calcium antagonist group of dihydropyridines generation III (type lacidipine, small spasms of the coronary arteries); d) assessment of risk of developing diabetes type II using drugs group preparations of thiazolidinediones (glitazones, insulinsensitizing), which is aimed at reducing insulin resistance of peripheral tissues (mostly at the level of muscle and fat, than at the level of the liver); d) regulation of synthesis of proteins involved in previously disturbed carbohydrate and lipid metabolism.
3. The author's methodology. Exclusion factors prochemical direction by engagement of balneation Kuban black sea coast, related to the prevention of the formation of the "syndrome victimize" due to excessive vasodilation and dysregulation of low density lipoprotein.Sachetana the provision of hypolipidemic and sistemtronik insulin-producenter effect of balneotherapy treatments, i.e. copyright drinking methods of applying bicarbonate-sodium chloride, alkaline, boric acid (with a high content of fluoride) natural mineral water "lasarevskoye healing".

Described in table 1 known methods of treatment of patients with metabolic disorders by type of lipidemia (E 78 ICD-X) in combination with non-insulin-dependent diabetes mellitus (E 11 ICD-X) does not include use for ingestion halogenated natural mineral waters resort of Sochi to achieve lipid-lowering effect and regulation of the manifestations of non-insulin dependent diabetes mellitus methods drinking balneotherapy using natural halogenated mineral water "lasarevskoye healing".

Known methods of prevention and treatment of metabolic disorders with the use of mineral waters, for example, in patent No. 2162697 [1] and # 2188024 [2].

However, the known methods do not envisage using for intake of halogenated natural mineral waters resort of Sochi to achieve lipid-lowering effect and regulation of the manifestations of non-insulin-dependent diabetes mellitus.

The authors developed a scientific method of non-drug treatment and prevention by drinking drinking natural mineral water "lasarevskoye healing"primordial concomitant disorders in persons from primary (n=279, p<0,05) group observations.

For the first time disclosed by the authors of the mechanism of action of halogenated natural mineral waters is based on the ability of monovalent fluorine (the content of which in the chemical formula, for example, natural mineral water "lasarevskoye healing" reaches as a specific component of 3.5 mg/l in the total mineralization called water 5,9-6,1 mg/l) more actively than traditional medical schemes to optimize not only the oxygen saturation level of blood in the microcirculatory level circulation, but also to positively influence the difference of the optical properties of hemoglobin fractions contained in the tested blood volume (1 ml) patients with impaired lipid metabolism in the background of non-insulin dependent diabetes diabetes.

Based on the above mechanism to increase oxygen saturation of the blood by the authors first investigated the effect on a specified group of patients drinking balneotherapy using bicarbonate-sodium chloride, alkaline, boric, with a high content of magnesium, iodine and fluoride in natural mineral water "lasarevskoye healing" wells No. 84-e Volkonsky field of Sochi (according to GOST R 54316-2011. Water natural mineral drinking. General specifications).

The prototype for this invention no. The analysis of the problem and the data of their own studies allowed the authors to conclude whether treatment of metabolic disorders (lipidemia), flowing sachetana with non-insulin-dependent diabetes mellitus to achieve high therapeutic effect claimed by way of drinking balneotherapy using natural mineral water "lasarevskoye healing".

The technical result achieved by the claimed invention is to improve health outcomes, i.e. the reduction of the original hypercholesterolemia, hypertriglyceridemia, stabilization (to normal), glycosylated hemoglobin and glucose tolerance test, the regeneration level of lipoproteins of low and high density plasma, compensation, performance poly - and nocturia, progressive obesity, pronounced before the holding of the drinking Spa treatment by the present method.

Another technical result of the proposed method is increased in patients indicators of quality of life (questionnaire Nottingham Healthe Profile") 1.8-2.5 times, including energy, work capacity, normal physical activity, the desire to participate in society, etc.

The invention

The technical result is achieved by a method for the prevention and treatment of metabolic disorders by type of lipidemia in combination with non-insulin-dependent diabetes mellitus includes the use of bicarbonate-sodium chloride, alkaline, Bo is Noah, with a high content of magnesium, iodine and fluorine, i.e. halogenated natural mineral water "lasarevskoye healing" wells No. 84-e Volkonsky field of Sochi by the following method: for 18-20 minutes before eating in small SIPS, 6 times a day, i.e. daily 180-200 ml at t=24-25°C for 40 days, with an interval of 3-5 days and repeat drinking receiving the same amounts of these natural mineral water for the next 40 days. In this case, the method includes the daily use of mineral water "lasarevskoye healing" at 8.00, 10.00, 12.00, 14.00, 16.00, 18.00 hours. Repetition of this course drinking balneotherapy, according to the invention, every three months for three years. This break between each of the four accepted annually for three years courses of treatment no more than 11-12 days.

Disclosure of inventions

The inventive method includes science-based drinking balneotherapy methods of correction of metabolic disorders by type of lipidemia in combination with non-insulin-dependent diabetes mellitus.

Method for the prevention and treatment of metabolic disorders by type of lipidemia (E 78 ICD-X) in combination with non-insulin-dependent diabetes mellitus (E 11 ICD-X) includes the use of bicarbonate-sodium chloride, alkaline, boric, with a high content of magnesium, iodine and fluorine, i.e. allowencodedslashes natural mineral water "lasarevskoye healing" wells No. 84-e Volkonsky field of Sochi by the following method: for 18-20 minutes before eating in small SIPS, 6 times a day, i.e. daily 180-200 ml at t=24-25°C for 40 days, with an interval of 3-5 days and repeat drinking receiving the same amounts of these natural mineral water for the next 40 days. The method includes the daily use of mineral water "lasarevskoye healing" at 8.00, 10.00, 12.00, 14.00, 16.00, 18.00 hours. Repetition of this course drinking balneotherapy, according to the invention, every three months for three years. This break between each of the four accepted annually for three years courses of treatment no more than 11-12 days.

Drinking mineral water with the trade name "lasarevskoye healing" refers to waters with low mineralization mineral medical-table water "lasarevskoye" and is extracted from the sources:

well No. 84-e Volkonsky deposits: mineral water of low salinity, bicarbonate-sodium chloride, alkaline, boric, with a high fluorine content.

The formula of the ionic composition and other characteristics of the water are shown in table 2.

Table 2
No. SLE.Name of state registration and trade nameThe formula of the ionic compositionSpecifications the AC, mg/DM3Flow rate, m3/dUse
No. 84-e Volkovskoe field"Lasarevskoye healing"H3BO3274,4 F3,5569,5

The content of Halogens (fluorine) in the chemical formula of natural mineral water "lasarevskoye healing" reaches as a specific component of 3.0-3.5 mg/l in the total mineralization called water 5,9-6,1 mg/l

As mentioned above, the mechanism of action of halogenated natural mineral waters is based on the ability of monovalent fluorine more actively than traditional medical schemes to optimize not only the oxygen saturation level of blood in the microcirculatory level circulation, but also to positively influence the difference of the optical properties of hemoglobin fractions contained in the tested blood volume (1 ml) patients with metabolic disorders by type of lipidemia in combination with non-insulin-dependent diabetes mellitus.

The Federal service for supervision of consumer rights protection and human welfare (Rospotrebnadzor), signed by the chief sanitary doctor, Onishchenko kind of is but the Certificate of state registration №U from 01.11.2006 is water mineral dining room "lasarevskoye healing" (THE 9185-002-95093915-06) passed the state registration, registered in the State register and approved for production on the territory of the Russian Federation, import and circulation on the territory of the Russian Federation (Annex 1). This certificate is issued on the basis of balneological conclusions SIC balneology and rehabilitation of the black sea zone control of specialized sanatorium of Ministry from 08.08.06, No. 75, Protocol ATL RDC "Quality" (№ROSS RU. AU) from 01.08.06, No. 1290. The validity of the certificate of state registration is set by the CPS for the entire period of the industrial production of Russian production or supply of imported goods (certificate number 0037130).

In addition, the Federal service for supervision of consumer rights protection and human welfare in the water mineral table "lasarevskoye healing" (THE 9185-002-95093915-06) issued by the Sanitary-epidemiological conclusion No. T from 01.11.2006, about the compliance of this mineral table water of the state sanitary-epidemiological rules and norms SanPiN 2.3.2. 1078-01 "Hygienic requirements for safety and nutrition value of food products". This sanitary-epidemiologies the e conclusion is also signed by the head of Rospotrebnadzor, Onishchenko (Appendix 2).

The empirical basis of the research was based on the dynamics of clinical manifestations of non-insulin-dependent diabetes mellitus and lipidemia. In this case, the observation units were formed by the method of unintentional selection 2 randomized (by age, gender, professional background and main clinical signs) group of patients with the abovementioned combined pathology (E 11 and E 78 ICD-X). The primary group of units of observations (n=279, p<0.05) in patients aged 30-40 years (including men 135 people or 48,4%; women - 144 people or 51.6 per cent), which in the pathogenesis of the disease was traced to hereditary factors that initiated the destruction of functions In cells and against laboratory-confirmed violations of the formation of insulin. It is clinically manifested by thirst, poly - and nocturia, fatigue, and in 88.5% of cases of obesity and other signs of non-insulin-dependent diabetes mellitus. Patients of control group observations (n=279, p<0,05) was sick with the already mentioned comorbidity (E 11 and E 78 ICD-X). They were identical (by age, sex, duration and symptoms of the disease) with the composition of the patients of the main group of observations, but the treatment of them was conducted at the outpatient stage without assigning circuits drinking balneotherapy according to the invention) while using the modern physician is bentosnyh regimens, aimed at key stages of pathogenesis of non-insulin-dependent diabetes mellitus and lipidemia, i.e. the correction of insulin resistance and features of S-cells, and compensation of hypercholesterolemia (GHS), hypertriglyceridemia (TG). Quality of life was assessed using the questionnaire Nottingham Healthe Profile (NHP), which to the greatest extent reflects the impact of the symptoms of the disease on patients ' quality of life (S.M. Hant, 2001) [Annex 1, paragraph 11]. The survey methodology consisted of two parts. In the first (NHP (I) was studied 6 basic parameters of quality of life study of patients with diabetes. Defined amount of quantitative indicators for each parameter source was taken as 100 points, which corresponded to the lowest quality of life in this parameter. The second part of the methodology (NHP II) was used to assess the impact of health status on the main types of daily activity of the patient. For obtaining objective results were used oral glucose tolerance test (especially when the selection of sanatorium treatment for those patients where a typical clinic diabetes was poorly expressed or absent). Impaired glucose tolerance was considered the content of glucose in venous and capillary blood (fasting) above 7 mmol/l; after 1 hour (venous blood) - above 10 mmol/l and 2 hours between 7 and 10 mmol/is. In capillary blood impaired glucose tolerance was recognized at values above 11 mmol/l and 2 hours, between 8 and 11 mmol/L. For data processing used the software CellQuest and WinMDI, v. 2.8 for processing data files of standard FCS 2.0. Statistical processing of data was performed using a computer software package STATISTICA 5.0 for WINDOWS 2007 (StatSoft Inc, USA). The significance of differences was evaluated by student's t-test. As the bases of research in the study were: a) municipal budget health care institution, Sochi City hospital №1"; b) Adler resort complex "Knowledge"; the Sochi Central military sanatorium; clinical Department of the fgbi "SIC balneology and rehabilitation" of FMBA of Russia.

The data in table 3, reveal the ability of natural halogenated mineral water "lasarevskoye healing" to ensure systemtray insulinproducing effects, including lipid-lowering and diuretic components. The latter is based on the obtained in the study, statistically reliable data compensation originally took place (when it arrives at the base of the study) in the clinic poly - and nocturia and progressive obesity, since upon completion of sanatorium rehabilitation at 98,6% (n=275, p<0,05)observed patients had adequate result on the stabilization measure glycated hemoglobin (claim 2 of 3 table 3).

Table 3
figure (p<0,05)The main group (n=279)Control gr. (n=279)
before the treatmentafterbefore the treatmentafter
1. Glucose tolerance test (mmol/l):
1.1. Venous blood:
- fasting (N<7)9,3±0,46,8±0,39,2±0,18,2±0,1
- after 1 hour (N<10)11,6±0,28,1±0,111,0±0,310,4±0,1
after 2 hours (N<7) 8,5±0,36,7±0,28,8±0,47,5±0,2
1.2. Capillary blood:
- fasting (N<7)9,2±0,56,9±0,29,3±0,27,6±0,2
- after 1 hour (N<11)12,7±0,69,8±0,112,6±0,511,4±0,1
after 2 hours (N<8)9,6±0,37,7±0,29,7±0,48,3±0,1
2. Glycosylated hemoglobin HbA1 (N=4,5-6,1%)7,14±0,11the 5.45±0,06was 7.08±0,096,59±0,03
3. Payment of the initial symptoms of thirst, the Oli and nocturia, fatigue, progressive obesity, etc.adequate resultadequate result
1,8% (n=5)to 98.6% (n=275)1,4% (n=4)to 72.4% (n=202)
4. Compensation hypercholesterolemia, hypertriglyceridemia; regeneration of LDL and HDL in the blood plasma1,07% (n=3)69,17% (n=193)0,71% (n=2)49,82% (n=139)

In addition, the authors used a standard glucose tolerance test (initially increased the examined patients) revealed a reduction of glucose levels in patients of the main group: (a) fasting from 9.3±0,4 to 6.8±0.3 mmol/l in venous blood and from 9.2±0,5 to 6.9±0.2 mmol/l in capillary blood; b) through h (N<10-11) - from 11.6±0,2 to 8.1±0.1 mmol/l and from 12.7±0,6 to 9.8±0.1 mmol/l, respectively; in two hours (when N<7-8), from 8.5 ą 0.3 to 6.7±0.2 mmol/l and 9.6±0,3 up to 7.7±0.2 mmol/l, respectively. In the control group these values were 1.1-1.2 times worse.

Proven direct correlative relationship between epicrise (at discharge from database research) and catamnestic the Kimi (a year later) the results of rehabilitation of patients with combined pathology E 11 and E 78 ICD-X (see table 4).

Table 4
Randomized (by age, sex, duration of disease, professional affiliation) groups of patients:discharged from database research in 2008-2012:
with substantial improvementswith the improvementwithout improvements
The main group (n=279, p<0,05)9,68% (n=27)89,25% (n=249)1,07% (n=3)
8,24% (n=23)90,69% (n=253)1,07% (n=3)
including the follow-up period (1 year after discharge)
Control group (n=279, p<0,05)or 4.31% (n=12)85,65%(n=239) 10,04%(n=28)
including the follow-up period (1 year after discharge)3,22% (n=9)86,74%(n=242)10,04%(n=28)
The quality of life of the patients by questionnaire Nottingham Healthe Profile":
a) the quality of life for NHP (part I)The main group*Control group*
patients with the target disease:before the treatmentafterbefore the treatmentafter
- energy41,9% (117)79,2% (221)43,3% (121)60,2% (168)
- pain68,4% (191)3,5% (10)67,4% (188)10,4% (29)
negative emotional reactions 98,5% (275)32,9% (92)97,5% (272)41,2% (115)
- reducing accommodativeness86,7% (242)23,3% (65)86,0% (240)31,1% (87)
normal physical activity29,0% (81)74,5% (208)29,7% (83)62,3% (174)
b) the quality of life for NHP (part II):
- normal working capacityto 38.3% (107)78,4% (219)39,1% (109)59,1% (165)
- participate in the conduct of the home. management30,8% (86)70,9% (198)32,2% (90)56,9% (159)
- active participation in society27,2% (76)53,0% (148)27,6% (77)47,6% (133)
- good interpersonal relations31.8% of (89)60,9% (170)31,5% (88)46,2% (129)
- sex life, including: MAR-test and15,7% (44)59,1% (165)16,1% (45)37,6% (105)
ELISA titer (methodology A. Gregoire and others)12,9% (36)60,5% (169)13,2% (37)44,0% (123)
- the desire for outdoor activities21,8% (61)51,2% (143)22,2% (62)48,3% (135)
Note: each patient the choice of a number of values NHP (part I and II) limiting the very.

This is confirmed by the increase in quality of life (questionnaire Nottingham Healthe Profile") in the observed patients, when energy, work capacity, normal physical activity, the pursuit of outdoor activities and participation in society increased in patients of the main group observation 1.8-2.5 times, whereas those in the control group were lower by 18-25%. Patients of the main group observations almost disappeared (except for 3.5% of the total number of observations) pain, decreased negative emotional reactions and establish good interpersonal relationships with others. In the control group observation (under the influence only of drug therapy) the same indicators of quality of life (analyzed by questionnaire Nottingham Healthe Profile") was 3 times lower.

Using the proposed method with the specified modes drinking balneotherapy can cut in the treatment of such metabolic type lipidemia in combination with non-insulin-dependent diabetes mellitus as primary hypercholesterolemia, hypertriglyceridemia, increased levels of glycosylated hemoglobin and values glucose tolerance test, as well as the content of the lipoprotein and high-density plasma on the background of poly - and nocturia, the program is shirousagi obesity, pronounced to conduct drinking balneotherapy treatment by the author's method. In addition, the claimed method at a statistically significant level observations (n=279, p<0,05) contributes to the compensation originally took place (when it arrives at the base of the study) in the clinic poly - and nocturia and progressive obesity, since upon completion of sanatorium rehabilitation at 98,6% (n=275, p<0,05) observed patients had adequate result on the stabilization measure glycated hemoglobin (see data table 3).

Regular use of the method described above medicinal drink natural mineral water "lasarevskoye healing" is in the form of innovative technologies normalization of glucose tolerance test, which was identified reduction of glucose levels in patients of the main group: (a) fasting from 9.3±0,4 to 6.8±0.3 mmol/l in venous blood and from 9.2±0,5 to 6.9±0.2 mmol/l in capillary blood; b) through h (N<10-11) - from 11.6±0,2 to 8.1±0.1 mmol/l and from 12.7±0.6 to 9,8±0.1 mmol/l, respectively; in two hours (when N<7-8), from 8.5 ą 0.3 to 6.7±0.2 mmol/l and 9.6±0,3 up to 7.7±0.2 mmol/l, respectively. In the control group these values were 1.1-1.2 times worse.

Illustration of therapeutic effectiveness of the proposed method is the fact that as a result of use for the implemented method of drinking balneotherapy hypolipidemic effect and normalization manifestations of non-insulin-dependent diabetes mellitus was carried out more successfully among patients of main group observations i.e. persons who have a history of natural drinking mineral water "lasarevskoye healing than patients in the control group observations treated by standard medical schemes described in claims 1 and 2 of table 1.

Taken into account that under the national Standard GOST R 54316-2011(natural mineral Water drinking) this mineral (5,0-6,0 g/DM3water does not imply limitations in daily and course doses consumption, and in the composition of its biologically active components present in industrial concentrations ions of boron, magnesium and fluoride. Examples of the method.

Example 1

Sick, Etc Cove, 35 years old, and a/b No. 1237, is under medical supervision in municipal budgetary health care institution, Sochi City hospital №1" (354000, Russia, Sochi, St. Petersburg, Constitution, etc. 24) with a diagnosis of non-insulin-dependent diabetes mellitus. Gipolipidemiceski syndrome. In the last 5 years diagnosed with diabetes mellitus type II, complains of thirst, weakness, fatigue, shortness of breath with light load or walking, weight gain, increased appetite, polyuria. Treated with xenicalcom (traditional dosages), passed medical compensation symptoms of hyperlipidemia and diabetes mellitus type II with drugs group preparations of thiazolidinediones (glitazones, insulinsensitizing), masticatory aimed at reducing insulin resistance of peripheral tissues (mainly on the level of muscle and fat, than at the level of the liver).

Objectively: the patient increased power (with the growth of 156 cm has a weight of 79 kg). The vesicular breathing, wheezing no. Heart sounds rhythmic, somewhat muted. Percutere: the borders of relative heart dullness in normal, wet tongue coated whitish bloom. The abdomen is soft, painless. Percutere border of the liver on the edge of the costal arch. Chair - irregular (the tendency to constipation). Urination free, painless, there are frequent urination, the frequent urination, excessive. Symptom of Pasternack negative on both sides. Urine color is straw yellow, stones, and sand during urination not sick notes.

Laboratory tests: complete blood count - hemoglobin 134 g/l, CVP,9, platelets 210×109the leukocytes of 5.4×109, EOS. 3, PAL. 1, segm. 73, limp. 26, mon. 8, ESR 15 mm/hour; total an. urine - tank weight 1012, transp. Full. reacts. acid, traces of protein and sugar, the epithelium is flat, small Qty, leukocytes 2-4 p./SREN., no mucus.

The body mass index (BMI) of 44.1±2.4 kg/cm2, waist (FROM) to 124.2±2.0 cm, hips (ABOUT) 119,4±2.6 cm, the ratio of body weight (in kg) and height (in cm) Quetelet Index II of 0.55 for N=0,41-0,49. Venous blood: on an empty stomach (N<7) to 9.3±0.4 mmol/l after 1 hour (N<10) to 11.6±0.2 mmol/l, 2 hours (N<7) 8,5±0.3 mmol/l in Capillary blood: on an empty stomach (N<7) of 9.2±0.5 mmol/l, the via 1 hour (N< 11) of 12.7±0.6 mmol/l, 2 hours (N<8) to 9.6±0.3 mmol/L. Glycosylated hemoglobin HbAl (N=4,5-6,1%) 7,14±0,11%. Triglycerides (TG) 197,8±2.3 mg/DL. High-density lipoprotein (HDL cholesterol) 25,1±1.6 mg/DL. Low-density lipoprotein (LDL) 156,2±6.4 mg/DL. LP (a) 57,3±0.9 mg/DL.

According to history, clinical, laboratory, instrumental and functional studies established the diagnosis of metabolic disorders by type of lipidemia (E 78 ICD-X) in combination with non-insulin-dependent diabetes mellitus (E 11 ICD-X).

Assigned treatment, including including the author's modes drinking balneotherapy (using bicarbonate-sodium chloride, alkaline, boric, with a high content of magnesium, iodine and fluoride in natural mineral water "lasarevskoye healing" wells No. 84-e Volkonsky field of Sochi by the following method: for 18 minutes before eating in small SIPS, 6 times a day, i.e. every day for 180 ml at t=24°C for 40 days (with a break for 3 days) and repeat drinking receiving the same amounts of these natural mineral water for the next 40 days. In this case, the method includes the daily use of mineral water "lasarevskoye healing" at 8.00, 10.00, 12.00, 14.00, 16.00, 18.00 hours. Repetition of this course drinking balneotherapy quarterly, i.e. the interval between each of the four accepted per year is about for three years courses of treatment reaches on a quarterly basis not more than 11 days.

As a result of the treatment: normalization of the initial symptoms of thirst and polyuria. Subjective notes the disappearance of the feeling of fatigue. Objectively: body mass index (BMI) 36,1±1.3 kg/cm2, waist (FROM) to 103.8±2.5 cm, hips (ABOUT) of 99.9±2.0 cm, the ratio of body weight (in kg) and height (in cm) Quetelet Index II 0,47 when N=0,41-0,49. Clinical and laboratory features: venous blood: on an empty stomach (N<7) of 6.8±0.3 mmol/l after 1 hour (N<10) to 8.1±0.1 mmol/l, 2 hours (N<7) of 6.7±0.2 mmol/l in Capillary blood: on an empty stomach (N<7) to 6.9±0.1 mmol/l after 1 hour (N<11) of 9.8±0.1 mmol/l, 2 hours (N<8) of 7.7±0.2 mmol/L. Glycosylated hemoglobin HbA1 (N=4,5-6,1%) 5,46±0,06%. Triglycerides (TG) covers 175.6±0,2 (N=173-177) mg/DL. High-density lipoprotein (HDL cholesterol) 29,2±0,6 (N=28-30) mg/DL. Low-density lipoprotein (LDL) 133,1±1,7 (N=132-135) mg/DL. PL (a) 54,6±0,2 (N=54-55) mg/DL. When analyzing the quality of life of observed patients in the questionnaire Nottingham Healthe Profile": pain is gone, negative emotional reactions to everyday conflicts are not notes. Believes that increased their social skills (willing to talk with people, and became more optimistic to relate it to the surrounding society on the background of subjective normalization own physical activity and disability). Thus, according to the current Standard of objective indicators of health the article [Annex 1, p.1] the patient, Etc Cove, 35 years old, and a/b No. 1237, held the claimed rate of drinking balneotherapy in municipal budgetary health care institution, Sochi City hospital №1" (354000, Russia, Sochi, St. Petersburg, Constitution, etc. 24), has completed the current phase of the clinical examination with a significant improvement in objective measures of health and subjective well-being.

Example 2

Sick Mustache-cue, 33 years old, and a/b No. 1492, during the 3 years is under medical supervision in municipal budgetary health care institution, Sochi City hospital №1" (354000, Russia, Sochi, St. Petersburg, Constitution, etc. 24) with a diagnosis of non-insulin-dependent diabetes mellitus, obesity II. Complaint: a constant feeling of thirst, fatigue with little exercise, inability to walk overcome without stopping distance more than 50-70 m Subjectively marks bulemia (constantly satisfies a false feeling of hunger by eating fatty foods). According to the patient urinates 8-10 times a day, including nighttime urination. The act of urination painless, load and with poor (70-100 ml per 1 time). The color of urine is dark yellow, odorless. The chair is irregular, the tendency to constipation, hard consistency, color dark. Objectively: the patient redundant power supply (when the height is 175 cm weighs 109 kg). The vesicular breathing, wheezing no. Heart sounds rhythmic, inv is the Schenna accent II tone of the aorta. Percutere: the borders of relative heart dullness within normal limits. HELL 142/89 mm Hg wet Tongue coated whitish bloom. The abdomen is soft, painless. Percutere border of the liver is on the edge of the costal arch. Symptom of Pasternack negative on both sides.

Laboratory tests: complete blood count - hemoglobin 125 g/l, Cup 1,0, platelets 210×109the leukocytes of 5.4×109, EOS. 3, PAL. 1, segm. 73, limp. 18, mon. 4, the sedimentation rate of 14 mm/hour; total an. urine - tank weight 1014, transp. Full. reacts. acid, traces of protein and sugar, the epithelium is flat, small Qty, leukocytes 2-3 p./SREN., no mucus.

The body mass index (BMI) 48,2±1.5 kg/cm2, waist (FROM) 119,6 cm, hips (ABOUT) to 116.2 cm, the ratio of body weight (in kg) and height (in cm) Quetelet Index II 0,57 when N=0,41-0,49. Venous blood: on an empty stomach (N<7) of 9.4±0.2 mmol/l after 1 hour (N<10) to 11.8±0.1 mmol/l, 2 hours (N<7) to 8.6±0.1 mmol/l in Capillary blood: on an empty stomach (N<7) to 9.3±0.4 mmol/l after 1 hour (N<11) to 12.8±0.3 mmol/l, 2 hours (N<8) of 9.7±0.2 mmol/HP Glycosylated hemoglobin HbA1 (N=4,5-6,1%) 7,25±0,8%. Triglycerides (TG) 198,3±1.2 mg/DL. High-density lipoprotein (HDL cholesterol), and 25.8±0.9 mg/DL. Low-density lipoprotein (LDL) 157,3±2.1 mg/DL.a-lipoproteins (LPa) 57,9±0.4 mg/DL.

According to history, clinical, laboratory, instrumental and functional studies diagnosed: the guy who lipidemia (E 78 ICD-X), flowing sachetana (within 3 years) with non-insulin-dependent diabetes mellitus (E 11 ICD-X).

Assigned treatment, including including the author's modes drinking balneotherapy (using bicarbonate-sodium chloride, alkaline, boric, with a high content of magnesium, iodine and fluoride in natural mineral water "lasarevskoye healing" wells No. 84-e Volkonsky field of Sochi by the following procedure: 20 minutes before eating in small SIPS, 6 times a day, i.e. daily 200 ml at t=25°C for 40 days (with a break of 5 days) and repeat drinking receiving the same amounts of these natural mineral water for the next 40 days. In this case, the method includes the daily use of mineral water "lasarevskoye healing" at 8.00, 10.00, 12.00, 14.00, 16.00, 18.00 hours. Repetition of this course drinking balneotherapy quarterly, i.e. the interval between each of the four accepted annually for three years courses of treatment reaches on a quarterly basis no more than 12 days.

As a result of the treatment: normalization of the initial symptoms of thirst and polyuria. Subjective notes the disappearance of the feeling of fatigue. Objectively: body mass index (BMI) of 38.2±1.0 kg/cm2when N=36-38 kg/cm2, waist (FROM) 106,9 cm (i.e. 10.6%), hips (ABOUT) 994 cm (i.e. decreased by 14.4%), the ratio of body weight (in kg) and height (in cm) Quetelet Index II 0,49 when N=0,41-0,49. Clinical and laboratory features: venous blood: on an empty stomach (N<7) to 6.9±0.1 mmol/l after 1 hour (N<10) of 8.3±0.2 mmol/l, 2 hours (N<7) to 6.8±0.1 mmol/l in Capillary blood: on an empty stomach (N<7) to 6.8±0.2 mmol/l after 1 hour (N<11) 10,0±0.3 mmol/l, 2 hours (N<8) of 7.8±0.1 mmol/L. Glycosylated hemoglobin HbA1 (N=4,5-6,1%) 5,81±0,05%. Triglycerides (TG) 176,3±0,03 (N=173-177) mg/DL. High-density lipoprotein (HDL cholesterol) 29,4±0,02 (N=28-30) mg/DL. Low-density lipoprotein (LDL) 134,6 of±0.02 (N=132-135) mg/DL. LP (a) 54,8±0,1 (N=54-55) mg/DL. When analyzing the quality of life of the patient on the questionnaire Nottingham Healthe Profile": pain no, negative emotional reactions to professional and personal conflicts notes is extremely rare, although the treatment of such phenomena wore a daily basis. Increased social awareness after regeneration own physical activity and disability (after weight loss began to wear t-shirts, jeans, another modern sports clothes cut that, in the opinion of the patient contributed to the restoration of positive psychological contact with colleagues or with strangers). Thus, according to the current Standard of objective health indicators [Annex 1, item 1] the patient Condition-cue, 33 years old, and a/b No. 1492 held the claimed rate of drinking balneotherapy in municipal budgetary health care institution, Sochi City hospital №1" (354000, Russia, Sochi, St. Petersburg, Constitution, etc. 24), has completed the current phase of the clinical examination with a significant improvement in objective measures of health and subjective well-being.

Sources of information

1. Patent No. 2162697 Way to prevent the progression of impaired glucose tolerance with the use of local Essentuki mineral water type (Published: 10.02.2001).

2. RF patent №2188024 method for the treatment of patients with alimentary-constitutional obesity with the use of diets with a high content of dietary fiber and mineral waters of low salinity (Published: 27.08.2002).

Appendix 1

References

1. Standards of objective health indicators. Information and methodological letter of the RF Ministry of health. - Moscow: Russian Ministry of health, 2004.-101 C.

2. Belenkov YU. et al. Assessment of myocardial viability: clinical aspects, research methods. - Cardiology. 2008. No. 1. - P.6 - 13.

3. Dedov I.I. et al. Introduction in diabetology. ): Beach, 2012. - 286 C.

4. Mamedov M.N. Guidelines for the diagnosis and treatment of metabolic syndrome. - Moscow: Publishing house of Multiprint, 2010. - P.52-53.

5. Marcinik E.N., Pastarus L.N., Tishchenko IV the efficiency of the control of diabetes. // Ukrainian. laboratory journal. - 2008. No. 2. - P.41-44.

6. Sidorenko B.A., Suvorov Y.A. Painless myocardial ischemia. // Cardiology. - 2005 - No. 12. - P.5-11.

7. Chazova IE, Kathuria SHE diabetes and cardiovascular disease. // Medical care. - 2001. No. 5. - P.28-32.

8. Cairns J.A., Gent M, Singer F., et al. Aspirin sulfmphyrazone, or both in unstable angina. N Engi JMed 2003:313:1369-75.

9. Cruickshank J.M. Technical standard of root canal treatment in an adult Scottish population. British Dental Journal 2004:183, 383-386.

10. Evequoz D., Erne P. Betablocker in der antihypertensiven Behandlung. Schweiz Rundsch Med-Prax 2008; 84(10):281-7.

11. Hant S.M. Nottingham Healthe Profile. // Eur. Heart J. - 2001. - Vol.26(19). - P. 153 to 159.

12. Iriarte, M., R. Caso, Mugra N. et al. Enalapril-induced regression of hypertensive left ventricular hypertrophy, regional ischemia, and microvascular angina. Amer J Cardiol 2012; 75:850-2.

13. Nestro R.W. et al. Thiazolidinedione use,fluid retention,and congestive heart failure:the consensus statement from the AHA and ADA Circulation 2011; 108:2941-2948.

14. Paul m, Ganten D. The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system. J Cardiovasc Pharmacol 2002; 19(Suppl 5):s51-s8.

15. Secree R., Shaw j, Zimmet P. Diabetes and impaired glucose toler-ance:prevalence and projection Diabetes atlas,2nd end Brussels international Diabetes Federation,2011:17-71.

16. Swedberg K, Cleland j, Dargie h, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 2005; 26 (11): 1115-40.

1. Method for the prevention and treatment of metabolic disorders by type of lipidemia in combination with non-insulin-dependent diabetes mellitus, including the use of halogenated hydro-carbonate-sodium chloride, alkaline, boric, with a high content of magnesium, iodine and fluoride in natural mineral water "lasarevskoye healing" wells is ins No. 84-e Volkonsky field of Sochi by the following method: for 18-20 minutes before eating in small SIPS, 6 times a day, every day at 180-200 ml at t=24-25°C for 40 days, with an interval of 3-5 days and repeat drinking receiving the same amounts of these natural mineral water for the next 40 days with a repetition rate of drinking balneotherapy every three months for three years.

2. The method according to claim 1, including daily consumption of mineral water "lasarevskoye healing" at 8.00, 10.00, 12.00, 14.00, 16.00, 18.00 hours.

3. The method according to claim 1, including a break between each of the four accepted annually for three years courses of treatment no more than 11-12 days.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to benzothiazine derivatives represented by general formula (I): 0, where R1 is a hydrogen atom; C1-C6 alkyl; COR5; SO2R5; CO(CH2)mOR6; (CH2)mR6; (CH2)mCONR7R8; (CH2)nNR7R8; (CH2)nOR6; CHR7OR9; (CH2)mR10; m assumes values from 1 to 6; n assumes values from 2 to 6; R2 is phenyl; naphthyl, 1,2,3,4-tetrahydro-naphthalene, biphenyl, phenylpyridine or a benzene ring condensed with a saturated or unsaturated monocyclic heterocycle containing 5-7 atoms and consisting of carbon atoms and 1-4 heteroatoms selected from N, O or S, other than indole, R3 is methyl or ethyl; R4 and R′4 are identical or different and denote a hydrogen atom; a halogen atom; C1-C6 alkyl; NR7R8; SO2Me; as well as stereoisomers, salts and solvates thereof, for therapeutic use and which are capable of inhibiting 11β-HSD1 on an enzymatic and cellular level.

EFFECT: obtaining benzothiazine derivatives.

17 cl, 197 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacy and medicine. What is presented is using a therapeutic agent containing a compound of the general formula

in a combination with at least one more therapeutic agent specified in biguanide and an α-glucosidase inhibitor for treating type 2 diabetes mellitus, diabetes complications, impaired glucose tolerance, insulin resistance or obesity, as well as the therapeutic agent based on the above combination for the same application.

EFFECT: technical effect consists in the synergetic action on an increase of the GLP-1 administration following administration of saccharose, a combination SK-0403 (a compound described by the general formula (I)) with Miglitol or metformin.

8 cl, 8 dwg, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutically acceptable (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)-butanoyl]-3-trifluoromethyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine-1-carboxylic acid salts, wherein an acid addition salt is specified in a group consisting of phosphate, malate and tartrate; a base addition salt is specified in a group consisting of sodium salt, lithium salt, potassium salt, calcium salt, magnesium salt, tetramethylammonium salt, tetraethylammonium salt, ethanolamine salt, choline salt and arginine salt. The invention also refers to methods for preparing the above salts, to a therapeutic agent as a dipeptidyl peptidase (DPP-IV) inhibitor based thereon.

EFFECT: there are prepared new (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)-butanoyl]-3-trifluoromethyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine-1-carboxylic acid salts which can find application in medicine as the therapeutic agent for treating type 2 diabetes, hyperglycemia, obesity or insulin resistance.

16 cl, 4 tbl, 13 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula , wherein A means a six-merous aryl radical or a five-merous heteroaryl radical which contains one heteroatom specified in oxygen and sulphur; one or more hydrogen atoms in the above aryl or heteroaryl radicals can be substituted by substituting groups R1 which are independently specified in a group consisting of: F, Cl, Br, I, (C1-C10)-alkyl-, (C1-C10)-alkoxy-, -NR13R14; B means a radical with mono- or condensed bicyclic rings specified in a group consisting of: six-ten-merous aryl radicals, five-ten-merous heteroaryl radicals and nine-fourteen-merous cycloheteroalkylaryl radicals, wherein cycloheteroalkyl links can be saturated or partially unsaturated, while the heterocyclic groups can contain one or more heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, one or more hydrogen atoms in the radical groups B can be substituted by substituting groups R5 (as specified in the patent claim), L means a covalent bond, X means the group -O-, R2 is absent or means one or more substitutes specified in F and (C1-C4)-alkyl radical; R3 and R4 independently mean (C1-C10)-alkyl, (C3-C14)-cycloalkyl, (C4-C20)-cycloalkylalkyl, (C2-C19)-cycloheteroalkyl, (C3-C19)-cycloheteroalkylalkyl, (C6-C10)-aryl, (C7-C20)-arylalkyl, (C1-C9)-heteroaryl, (C2-C19)-heteroarylalkyl radicals, or R3 and R4 together with nitrogen attached whereto can form a four-ten-merous saturated, unsaturated or partially unsaturated heterocyclic compound which can additionally contain one or more heteroatoms among -O-, -S(O)n-, =N- and -NR8-; other radicals are such as specified in the patient claim. Also, the invention refers to using the compound of formula I for preparing a drug.

EFFECT: compounds of formula (I) as Na+/H+ metabolism inhibitors NHE3.

22 cl, 27 dwg, 1 tbl, 756 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry, and represents using a biologically active agent for preparing a drug for metabolic disorders specified in a group consisting of insulin resistance syndrome and diabetes mellitus, including type I diabetes mellitus and type II diabetes mellitus, and obesity, wherein the agent represents a compound of formula

,

wherein n=1 or 2; m=0, 1, 2, 4 or 5; q=0; t=0 or 1; R3 represents hydrogen; A is phenyl, unsubstituted or substituted by 1 or 2 alkyls having 1 or 2 carbon atoms; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms; or when R1 represents hydrogen - a pharmaceutically acceptable salt of the compound.

EFFECT: preparing the drug for metabolic disorders.

18 cl, 6 ex, 22 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of structural formula or a salt thereof, where each of Z1, Z2 and Z3 is independently selected from N and C(R9), where not more than one of Z1, Z2 and Z3 is N; each R9 is hydrogen; and is a second chemical bond between either W2 and C(R12), or W1 and C(R12); W1 is -N=, and W2(R14) is selected from -N(R14)- and -C(R14)=, such that when W1 is -N=, W2(R14) is -N(R14)- and is a second chemical bond between W1 and C(R12); R11 is selected from phenyl and a heterocycle which is selected from a saturated or aromatic 5-6-member monocyclic ring, which contains one or two or three heteroatoms selected from N, O and S, or an 8-member bicyclic ring which contains one or more heteroatoms selected from N, O and S, where R11 is optionally substituted with one or two substitutes independently selected from halogen, C1-C4 alkyl, =O, -O-R13, -(C1-C4 alkyl)-N(R13)(R13), -N(R13)(R13), where each R13 is independently selected from -C1-C4alkyl; or two R13 together with a nitrogen atom to which they are bonded form a 5-6-member saturated heterocycle, optionally containing an additional heteroatom selected from NH and O, where if R13 is an alkyl, the alkyl is optionally substituted with one or more substitutes selected from -OH, fluorine, and if two R13 together with the nitrogen atom to which they are bonded form a 5-6-member saturated heterocycle, the saturated heterocycle is optionally substituted on any carbon atom with fluorine; R12 is selected from phenyl, a 4-6-member monocyclic saturated ring and a heterocycle, which is selected from an aromatic 5-6-member monocyclic ring which contains one or two heteroatoms selected from N and S, where R12 is optionally substituted with one or more substitutes independently selected from halogen, -C≡N, C1-C4 alkyl, C1-C2 fluorine-substituted alkyl, -O-R13, -S(O)2-R13, -(C1-C4 alkyl)-N(R13)(R13), -N(R13)(R13); R14 is selected from hydrogen, C1-C4 alkyl, C1-C4 fluorine-substituted alkyl, C1-C4 alkyl-N(R13)(R13), C1-C4 alkyl-C(O)-N(R13)(R13); and X1 is selected from -NH-C(=O)-†, -C(=O)-NH-†, -NH-S(=O)2-†, where † denotes the point where X1 is bonded to R11. The invention also relates to a pharmaceutical composition having sirtuin modelling activity based on said compounds.

EFFECT: obtaining novel compounds and a pharmaceutical composition based on said compounds, which can be used in medicine to treat a subject suffering from or susceptible to insulin resistance, metabolic syndrome, diabetes or complications thereof.

18 cl, 2 tbl, 52 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents a pharmaceutical composition for prevention and treatment of the metabolic syndrome and diabetic nephropathy, which contains the following active substances: taurine, a dry extract of motherwort herb, a dry extract of hawthorn fruit and accessory substances, with components present in the composition in a specified ratio in wt %.

EFFECT: invention provides extension of the arsenal of means for prevention and treatment of the metabolic syndrome and diabetic nephropathy.

10 cl, 13 ex, 19 tbl

FIELD: medicine.

SUBSTANCE: group of inventions relates to an improved method of controlling glycemia in a patient with the second type of diabetes, who is being treated with a suppressor of glucose production by the liver, including a stage of introduction of a superfast-acting insulin preparation to the patient in the mode of glycemia control, where the superfast-acting insulin preparation is introduced instead of an insulin secretion intensifier during intake of food, and where the patient continues receiving the suppressor of glucose production by the liver The group of inventions also relates to improved methods of treating hyperglycemia in patients with the second type of diabetes, who are being treated with the suppressor of glucose production by the liver and the insulin secretion intensifier, with superfast-acting insulin.

EFFECT: application of the obtained group of inventions makes it possible to achieve an improved glycemya control and treatment.

33 cl, 28 dwg, 4 ex

FIELD: chemistry, pharmacology.

SUBSTANCE: invention represents pharmaceutical composition for peroral application and reduction of glucose level in blood, which contains insulin, water-soluble organic acid, water-soluble inert filling agent and auxiliary substance, characterised by the fact that as auxiliary substance it contains sodium carbonate or bicarbonate, and as water-soluble organic acid - citric acid or tartaric acid, or ascorbic acid, or lactic acid, and quantity of sodium carbonate or bicarbonate must be 2-6 times less than the quantity of specified organic acid, with composition components being in specified ratio in wt %.

EFFECT: acceleration and simplification of the process of composition application, as well as prevention of undesirable impact of inhibitor of proteolytic enzymes on digestion in small intestine and elimination of risk of penetration of biologically active substance different from insulin into blood, without decrease or with increase of efficiency with reduction of insulin concentration, elimination of risk of temporary increase of glucose level.

4 tbl, 5 ex

FIELD: chemistry, pharmacology.

SUBSTANCE: group of inventions relates to insulin conjugate, possessing improved action duration and stability in vivo, obtained by covalent binding of insulin with Fc region of immunoglobulin via non-peptidyl polymer, as well as to composition of prolonged action, which contains it, and to method of their obtaining.

EFFECT: support of insulin activity in vivo at relatively high level and considerable increase of period of its serum half-life, with considerable increase of improvement of medication intake regimen in comparison with insulin therapy.

21 cl, 8 ex, 6 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gastroenterology and endocrinology, and concerns treating patients suffering from dyspepsia syndrome in a combination with overweight. That is ensured by therapy with preparations improving metabolism, promoting weight loss and fat absorption, as well as antidepressants. The therapy is differentiated taking into account an anxiety level (HARS) and a depression level (HDRS) according to Hamilton rating scales, nutritional status assessed by bioimpedancemetry, a degree of manifestation of sleep disorders, eating behaviour typing, eating regimen and daily rhythm determination , level evaluation of glucose, immunoreactive insulin, cholesterol, high-density lipoprotein (HDLP), triglyceride in venous blood, blood glucose tolerance, gustation, life quality assessment.

EFFECT: differentiated approach provides an effective treatment of dyspepsia in a combination with weight loss, correction of eating behaviour and metabolic processes.

2 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely to an agent with an antidyslipidemic and analgesic effect. The method for preparing the phytocomplex with the antidyslipidemic and analgesic effect, involving: a) grinding peeled bergamot fruit to prepare an undegraded mixture, b) introducing pectinolytic enzymes into the mixture; c) reducing pulp content; d) inactivating the above enzymes added at the stage b), to prepare a degraded mixture; e) performing ultrafiltration of the degraded mixture through membranes isolating the substances having a molecular weight of over 30,000 Da, to prepare a transparent solution; f) introducing the transparent solution on a polyphenol absorption column; g) washing the polyphenol absorption column with water and increasing pH to prepare an aqueous polyphenol fraction; h) transmitting the aqueous polyphenol fraction to cationic resin to recover the phytocomplex in an aqueous phase; i) drying the phytocomplex in the aqueous phase. The phytocomplex in the aqueous phase with the antidyslipidemic and analgesic effect. The phytocomplex with the antidyslipidemic and analgesic effect. A pharmaceutical composition with the antidyslipidemic effect containing the phytocomplex, and pharmaceutically acceptable additives. A pharmaceutical composition with the analgesic effect containing the phytocomplex, and pharmaceutically acceptable additives.

EFFECT: phytocomplex described above possesses the evident antidyslipidemic and analgesic effect.

11 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula , wherein A means a six-merous aryl radical or a five-merous heteroaryl radical which contains one heteroatom specified in oxygen and sulphur; one or more hydrogen atoms in the above aryl or heteroaryl radicals can be substituted by substituting groups R1 which are independently specified in a group consisting of: F, Cl, Br, I, (C1-C10)-alkyl-, (C1-C10)-alkoxy-, -NR13R14; B means a radical with mono- or condensed bicyclic rings specified in a group consisting of: six-ten-merous aryl radicals, five-ten-merous heteroaryl radicals and nine-fourteen-merous cycloheteroalkylaryl radicals, wherein cycloheteroalkyl links can be saturated or partially unsaturated, while the heterocyclic groups can contain one or more heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, one or more hydrogen atoms in the radical groups B can be substituted by substituting groups R5 (as specified in the patent claim), L means a covalent bond, X means the group -O-, R2 is absent or means one or more substitutes specified in F and (C1-C4)-alkyl radical; R3 and R4 independently mean (C1-C10)-alkyl, (C3-C14)-cycloalkyl, (C4-C20)-cycloalkylalkyl, (C2-C19)-cycloheteroalkyl, (C3-C19)-cycloheteroalkylalkyl, (C6-C10)-aryl, (C7-C20)-arylalkyl, (C1-C9)-heteroaryl, (C2-C19)-heteroarylalkyl radicals, or R3 and R4 together with nitrogen attached whereto can form a four-ten-merous saturated, unsaturated or partially unsaturated heterocyclic compound which can additionally contain one or more heteroatoms among -O-, -S(O)n-, =N- and -NR8-; other radicals are such as specified in the patient claim. Also, the invention refers to using the compound of formula I for preparing a drug.

EFFECT: compounds of formula (I) as Na+/H+ metabolism inhibitors NHE3.

22 cl, 27 dwg, 1 tbl, 756 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry, and represents using a biologically active agent for preparing a drug for metabolic disorders specified in a group consisting of insulin resistance syndrome and diabetes mellitus, including type I diabetes mellitus and type II diabetes mellitus, and obesity, wherein the agent represents a compound of formula

,

wherein n=1 or 2; m=0, 1, 2, 4 or 5; q=0; t=0 or 1; R3 represents hydrogen; A is phenyl, unsubstituted or substituted by 1 or 2 alkyls having 1 or 2 carbon atoms; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms; or when R1 represents hydrogen - a pharmaceutically acceptable salt of the compound.

EFFECT: preparing the drug for metabolic disorders.

18 cl, 6 ex, 22 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents a pharmaceutical composition for prevention and treatment of the metabolic syndrome and diabetic nephropathy, which contains the following active substances: taurine, a dry extract of motherwort herb, a dry extract of hawthorn fruit and accessory substances, with components present in the composition in a specified ratio in wt %.

EFFECT: invention provides extension of the arsenal of means for prevention and treatment of the metabolic syndrome and diabetic nephropathy.

10 cl, 13 ex, 19 tbl

FIELD: medicine.

SUBSTANCE: present group of inventions refers to medicine, namely to therapy and cardiology, and concerns lowering triglycerides without increasing LDL cholesterol in an individual receiving a concomitant statin therapy with initial fasting triglycerides 200 mg/dl to 500 mg/dl. That is ensured by administering ethyl eicosapentaenoate 4 g a day additionally.

EFFECT: invention provides lowering both total triglycerides, and low-density lipoproteins.

30 cl, 6 tbl

FIELD: chemistry.

SUBSTANCE: compound has formula I: |Chemical formula 1| where A is O, NR, S, S(=O), S(=O)2 or Sc; B is hydrogen or ; R1 is hydrogen, C1-C8 alkyl or halogen; R2 is hydrogen, C1-C8 alkyl, or ; Xa and Xb is independently CR or N; R is hydrogen or C1-C8 alkyl; R3 is hydrogen, C1-C8 alkyl; R4 and R5 are independently hydrogen, halogen or C1-C8 alkyl; R6, is hydrogen. C1-C8 alkyl, or a pharmaceutically acceptable organic salt; R21, R22 and R23 are independently hydrogen, halogen, NO2, C1-C7 alkyl, unsubstituted or substituted with halogen, C3-C12 heteroaryl, containing one or more heteroatoms selected from N, O and S; m equals an integer from 1 to 4; p equals an integer from 1 to 5; s equals an integer from 1 to 5; u equals an integer from 1 to 3; w equals an integer from 1 to 4; and alkyl in R1, R3, R4, R5 and R6 can further be substituted with one or more halogens, C3-C7 cycloalkyl or C1-C5 alkylamine. Also disclosed are methods of producing selenazole derivatives, a pharmaceutical composition, a functional feed additive composition, a functional beverage, a food additive, animal feed, a functional cosmetic composition, a peroxisome proliferator-activated receptor (PPAR) activator composition.

EFFECT: invention enables to obtain a selenazole derivative which activates a peroxisome proliferator-activated receptor.

15 cl, 1 dwg, 6 tbl, 298 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, more specifically to an agent that can be used for treating the lipid storage disease. A pharmaceutical composition contains calcium rosuvastatin in the therapeutically effective amount, lactose as an excipient containing 94.7-98.3 wt % of lactose monohydrate and povidone, cross povidone as a desintegrant, colloidal silicone dioxide as a glidant, stearate as a lubricant, with the composition containing an inorganic salt with a polyvalent cation. The pharmaceutical composition according to the invention is characterised by the substantial reduction of calcium rosuvastatin storage destruction, fast disintegration, high release rate of the active agent, high breaking and abrasive strength, and has a shelf life of more than 2 years.

EFFECT: preparing the agent that can be used for treating the lipid storage disease.

5 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: pharmaceutical composition in a dose of 4 g a day containing at least 90 wt % of ethyl eicosapentaenoate is administered into an individual having initial fasting triglycerides within the approximate range of 500 mg/dl to 2000 mg/dl for a period of time effective to reduce fasting triglycerides by at least 15% as compared to initial fasting triglycerides before the first administration of the pharmaceutical composition. The second version involves administering approximately 4 g a day of the pharmaceutical composition containing at least 96 wt % ethyl eicosapentaenoate into an individual with initial fasting triglycerides from approximately 500 mg/dl to approximately 2000 mg/dl receiving neither any pharmaceutical composition, nor a concomitant statin therapy, for a period of time effective to reduce fasting triglycerides by at least 25% as compared to another similar individual. The third version provides reducing triglycerides and apoliprotein B in an individual having initial fasting triglycerides from approximately 500 mg/dl to approximately 2000 mg/dl and receiving no concomitant therapy changing the lipid profile, and involves administering approximately 4 g a day of the pharmaceutical composition containing at least 96 wt % of ethyl eicosapentaenoate for a 12-week period. The individual shows the fasting triglycerides reduction by at least 25% and the fasting apoliprotein B reduction as compared to the reference having initial triglycerides within the range from 500 mg/dl to approximately 2000 mg/dl and receiving neither any pharmaceutical composition, nor a concomitant therapy changing the lipid profile.

EFFECT: method improvement.

4 cl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel 4-trimethylammonio-butyrates of formula I

,

where A1, R1, m and n are as defined in the description and in the claim, as well as pharmaceutically acceptable salts thereof.

EFFECT: compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments for therapeutic or preventive treatment of hyperglycemia, glucose tolerance disorders, diabetes and associated pathologies, non-insulin dependent diabetes mellitus, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure.

13 cl, 1 tbl, 39 ex

FIELD: medicine.

SUBSTANCE: according to one version, the method involves studying the heart rate variability and a motion state, dietary nutrition, baths with mineral water, mineral water intake, physiotherapeutic procedures. The dietary regimen is specified taking into account the measured immunoglobulin IgG values to detect food intolerance and elimination thereof from the nutrition. Low-salt sulphate calcium-magnesium-sodium mineral water is taken. The baths are taken with mineral water from a water-bearing formation of Middle Devonian at a depth of 1100-1278 m by using mineral water representing a salt brine of Devonian Sea M 240-260 g/dm3 of sodium-chloride composition Cl>95, Na++K+>80 mg-eq.%, with an acid reaction of the medium, at pH 4.7-5.5. According to the other version, the method additionally contains massage sessions and acupuncture taking into account the patient's heart rate variability.

EFFECT: group of inventions provides more effective health improvement by taking into account individual food intolerance and the patient's autonomic nervous system features.

2 cl, 3 ex

Up!